Cargando…

Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease

BACKGROUND AND PURPOSE: Oxidative stress is involved in the pathophysiological mechanisms of stroke (e.g., atherosclerosis) and brain injury after ischemic stroke. Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have both pleiotropic and low-density lipoprotein (LDL...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Gyeong Joon, Kim, Suk Jae, Cho, Yeon Hee, Ryoo, Sookyung, Bang, Oh Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017017/
https://www.ncbi.nlm.nih.gov/pubmed/24829600
http://dx.doi.org/10.3988/jcn.2014.10.2.140
_version_ 1782315601967972352
author Moon, Gyeong Joon
Kim, Suk Jae
Cho, Yeon Hee
Ryoo, Sookyung
Bang, Oh Young
author_facet Moon, Gyeong Joon
Kim, Suk Jae
Cho, Yeon Hee
Ryoo, Sookyung
Bang, Oh Young
author_sort Moon, Gyeong Joon
collection PubMed
description BACKGROUND AND PURPOSE: Oxidative stress is involved in the pathophysiological mechanisms of stroke (e.g., atherosclerosis) and brain injury after ischemic stroke. Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have both pleiotropic and low-density lipoprotein (LDL)-lowering properties. Recent trials have shown that high-dose statins reduce the risk of cerebrovascular events. However, there is a paucity of data regarding the changes in the oxidative stress markers in patients with atherosclerotic stroke after statin use. This study evaluated changes in oxidative stress markers after short-term use of a high-dose statin in patients with atherosclerotic stroke. METHODS: Rosuvastatin was administered at a dose of 20 mg/day to 99 patients who had suffered an atherosclerotic stroke and no prior statin use. Blood samples were collected before and 1 month after dosing, and the serum levels of four oxidative stress markers-malondialdehyde (MDA), oxidized LDL (oxLDL), protein carbonyl content (PCO), and 8-hydroxy-2'-deoxyguanosine (8-OHdG)-were evaluated to determine the oxidation of MDA and lipids, proteins, and DNA, respectively, at both of those time points. RESULTS: The baseline levels and the degrees of reduction after statin use differed among the oxidative stress markers measured. MDA and PCO levels were associated with infarct volumes on diffusion-weighted imaging (r=0.551, p<0.05, and r=0.444, p=0.05, respectively). Statin use decreased MDA and oxLDL levels (both p<0.05) but not the PCO or 8-OHdG level. While the reduction in MDA levels after statin use was not associated with changes in cholesterol, that in oxLDL levels was proportional to the reductions in cholesterol (r=0.479, p<0.01), LDL (r=0.459, p<0.01), and apolipoprotein B (r=0.444, p<0.05). CONCLUSIONS: The impact of individual oxidative stress markers differs with time after ischemic stroke, suggesting that different oxidative markers reflect different aspects of oxidative stress. In addition, short-term use of a statin exerts antioxidant effects against lipid peroxidation via lipid-lowering-dependent and -independent mechanisms, but not against protein or DNA oxidation in atherosclerotic stroke patients.
format Online
Article
Text
id pubmed-4017017
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Korean Neurological Association
record_format MEDLINE/PubMed
spelling pubmed-40170172014-05-14 Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease Moon, Gyeong Joon Kim, Suk Jae Cho, Yeon Hee Ryoo, Sookyung Bang, Oh Young J Clin Neurol Original Article BACKGROUND AND PURPOSE: Oxidative stress is involved in the pathophysiological mechanisms of stroke (e.g., atherosclerosis) and brain injury after ischemic stroke. Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, have both pleiotropic and low-density lipoprotein (LDL)-lowering properties. Recent trials have shown that high-dose statins reduce the risk of cerebrovascular events. However, there is a paucity of data regarding the changes in the oxidative stress markers in patients with atherosclerotic stroke after statin use. This study evaluated changes in oxidative stress markers after short-term use of a high-dose statin in patients with atherosclerotic stroke. METHODS: Rosuvastatin was administered at a dose of 20 mg/day to 99 patients who had suffered an atherosclerotic stroke and no prior statin use. Blood samples were collected before and 1 month after dosing, and the serum levels of four oxidative stress markers-malondialdehyde (MDA), oxidized LDL (oxLDL), protein carbonyl content (PCO), and 8-hydroxy-2'-deoxyguanosine (8-OHdG)-were evaluated to determine the oxidation of MDA and lipids, proteins, and DNA, respectively, at both of those time points. RESULTS: The baseline levels and the degrees of reduction after statin use differed among the oxidative stress markers measured. MDA and PCO levels were associated with infarct volumes on diffusion-weighted imaging (r=0.551, p<0.05, and r=0.444, p=0.05, respectively). Statin use decreased MDA and oxLDL levels (both p<0.05) but not the PCO or 8-OHdG level. While the reduction in MDA levels after statin use was not associated with changes in cholesterol, that in oxLDL levels was proportional to the reductions in cholesterol (r=0.479, p<0.01), LDL (r=0.459, p<0.01), and apolipoprotein B (r=0.444, p<0.05). CONCLUSIONS: The impact of individual oxidative stress markers differs with time after ischemic stroke, suggesting that different oxidative markers reflect different aspects of oxidative stress. In addition, short-term use of a statin exerts antioxidant effects against lipid peroxidation via lipid-lowering-dependent and -independent mechanisms, but not against protein or DNA oxidation in atherosclerotic stroke patients. Korean Neurological Association 2014-04 2014-04-23 /pmc/articles/PMC4017017/ /pubmed/24829600 http://dx.doi.org/10.3988/jcn.2014.10.2.140 Text en Copyright © 2014 Korean Neurological Association http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Moon, Gyeong Joon
Kim, Suk Jae
Cho, Yeon Hee
Ryoo, Sookyung
Bang, Oh Young
Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
title Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
title_full Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
title_fullStr Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
title_full_unstemmed Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
title_short Antioxidant Effects of Statins in Patients with Atherosclerotic Cerebrovascular Disease
title_sort antioxidant effects of statins in patients with atherosclerotic cerebrovascular disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017017/
https://www.ncbi.nlm.nih.gov/pubmed/24829600
http://dx.doi.org/10.3988/jcn.2014.10.2.140
work_keys_str_mv AT moongyeongjoon antioxidanteffectsofstatinsinpatientswithatheroscleroticcerebrovasculardisease
AT kimsukjae antioxidanteffectsofstatinsinpatientswithatheroscleroticcerebrovasculardisease
AT choyeonhee antioxidanteffectsofstatinsinpatientswithatheroscleroticcerebrovasculardisease
AT ryoosookyung antioxidanteffectsofstatinsinpatientswithatheroscleroticcerebrovasculardisease
AT bangohyoung antioxidanteffectsofstatinsinpatientswithatheroscleroticcerebrovasculardisease